close-up photo of a man wearing eyeglasses who is very interesed in whatever he is looking at

News Releases

November 8, 2021

Almirall U.S. Supports The Skin Cancer Foundation's Mobile Skin Cancer Screening Program

February 18, 2021

Almirall U.S. Launches Klisyri® (tirbanibulin), a New, Innovative Topical Treatment for Actinic Keratosis

February 11, 2021

Almirall Announces New England Journal of Medicine Publication of Phase III Data Demonstrating Efficacy and Safety of Klisyri® (tirbanibulin)

December 15, 2020

Almirall Announces FDA Approval of Klisyri® (tirbanibulin), a New Innovative Topical Treatment for Actinic Keratosis

November 18, 2020

Almirall appoints Pablo Alvarez as President and General Manager of US organization

June 18, 2020

Almirall Announces FDA Approval Of Updated Label For SEYSARA® (sarecycline) Tablets

January 9, 2020

Almirall and WuXi Biologics Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases

January 9, 2020

Almirall Signs A Strategic Agreement With 23andMe To License Rights Of A Bispecific Monoclonal Antibody That Blocks All Three Isoforms Of IL-36 Cytokine

January 8, 2020

Almirall Enters Into an Option Agreement to Acquire Bioniz Therapeutics and to Establish a Broad Research Agreement to Further Expand Its Innovative Pipeline in Medical Dermatology

December 6, 2019

Almirall LLC Announces The Publication Of Long-Term Safety Data For The Use Of Seysara® (sarecycline) Tablets In Patients 9 Years Of Age And Older

September 10, 2019

ACZONE® (dapsone) GEL, 7.5% Now Approved For The Topical Treatment Of Acne Vulgaris In Patients 9 Years Of Age And Older

July 25, 2019

Almirall Issues Call for Grant Submissions for Development of New Immunodermatology Therapies through Almirallshare

June 17, 2019

Almirall Partners with AARS to Raise Awareness about the Burden of Disease and Importance of Education for Dermatology Professionals for National Acne Awareness Month

May 13, 2019

Almirall Q1 2019. Strong operating performance

April 11, 2019

Almirall Recognized As Distinguished Corporate Leader By American Skin Association - Unveiled Patient-Driven Purpose

March 4, 2019

Almirall and Athenex Announce Positive Topline Results from Two Phase III Studies of KX2-391 Ointment 1% Featured in Late Breaker Program at the 2019 American Academy of Dermatology Annual Meeting

March 4, 2019

Almirall enters into a definitive agreement to divest ThermiGen, its medical device aesthetics business

January 17, 2019

Novel Oral Antibiotic SEYSARA™ (sarecycline) Now Available

October 19, 2018

Almirall LLC Launches New Name at Fall Clinical Dermatology Congress

September 21, 2018

Almirall acquires Allergan U.S. medical dermatology portfolio

Media Inquiries
media.us@almirall.com

Almirall PR
almirallpr.us@almirall.com